Parkinson disease mutant E46K enhances α-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo

Journal of Biological Chemistry

Volumn 290, Issue 15, 2015, Pages 9412-9427

  Mbefo, Martial Kamdem ^a   Fares, Mohamed Bilal ^a   Paleologou, Katerina ^a   Oueslati, Abid ^a   Yin, Guowei ^b   Tenreiro, Sandra ^c   Pinto, Madalena ^c   Outeiro, Tiago ^c,d,e   Zweckstetter, Markus ^b,f   Masliah, Eliezer ^g   Lashuel, Hilal A ^a  

^a EPFL   (Switzerland)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^c Instituto de Medicina Molecular   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL MEMBRANES; DISEASES; ENZYMES; MAMMALS; YEAST;

DIFFERENT MECHANISMS; ENDOPLASMIC RETICULUM; IN-VIVO; KINASE SUBSTRATES; MAMMALIAN CELL LINES; OVER-EXPRESSION; PARKINSON DISEASE; SYNUCLEIN;

PHOSPHORYLATION;

ALPHA SYNUCLEIN; CASEIN KINASE I; PLK2 PROTEIN, HUMAN; PROTEASOME; PROTEIN SERINE THREONINE KINASE; SERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOLYSIS; ENDOPLASMIC RETICULUM; FUNGAL STRAIN; GENETIC TRANSFECTION; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MALE; MAMMAL CELL; MICROSOME; MOUSE; MUTANT; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; WILD TYPE; YEAST CELL; ANIMAL; BRAIN; C57BL MOUSE; CELL NUCLEUS; CONFOCAL MICROSCOPY; ENZYME SPECIFICITY; GENETICS; HIPPOCAMPUS; KINETICS; METABOLISM; MUTATION; PHOSPHORYLATION; SACCHAROMYCES CEREVISIAE; WESTERN BLOTTING;

LENTIVIRUS; MAMMALIA; MUS;

ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; BRAIN; CASEIN KINASE I; CELL NUCLEUS; ENDOPLASMIC RETICULUM; HEK293 CELLS; HELA CELLS; HIPPOCAMPUS; HUMANS; KINETICS; MALE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MUTATION; PARKINSON DISEASE; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; SACCHAROMYCES CEREVISIAE; SERINE; SUBSTRATE SPECIFICITY;

EID: 84927144360     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.610774     Document Type: Article

References (79)

1. Oueslati, A., Fournier, M., and Lashuel, H. A. (2010) Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183, 115-145
2. Golbe, L. I., Di Iorio, G., Bonavita, V., Miller, D. C., and Duvoisin, R. C. (1990) A large kindred with autosomal dominant Parkinson's disease. Ann. Neurol. 27, 276-282
3. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047
4. Puschmann, A., Ross, O. A., Vilariño-Güell, C., Lincoln, S. J., Kachergus, J. M., Cobb, S. A., Lindquist, S. G., Nielsen, J. E., Wszolek, Z. K., Farrer, M., Widner, H., van Westen, D., Hägerström, D., Markopoulou, K., Chase, B. A., et al. (2009) A Swedish family with de novo α-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat. Disord. 15, 627-632
5. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schöls, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108
6. Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Muñoz, D. G., and de Yebenes, J. G. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173
7. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J., Aasly, J. O., Rajput, A., Rajput, A. H., Jon Stoessl, A., and Farrer, M. J. (2013) α-Synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28, 811-813
8. Proukakis, C., Dudzik, C. G., Brier, T., MacKay, D. S., Cooper, J. M., Millhauser, G. L., Houlden, H., and Schapira, A. H. (2013) A novel α-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064
9. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., Madiona, K., Dürr, A., Melki, R., Verny, C., Brice, A., and French Parkinson's Disease Genetics Study Group. (2013) G51D α-Synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459-471
10. Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen, J., Tienari, P. J., Pöyhönen, M., and Paetau, A. (2014) A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 35, 2180
11. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., and Lansbury, P. T., Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715
12. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449
13. Bertoncini, C. W., Jung, Y. S., Fernandez, C. O., Hoyer, W., Griesinger, C., Jovin, T. M., and Zweckstetter, M. (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured α-synuclein. Proc. Natl. Acad. Sci. U.S.A. 102, 1430-1435
14. Schmid, A. W., Chiappe, D., Pignat, V., Grimminger, V., Hang, I., Moniatte, M., and Lashuel, H. A. (2009) Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of α-synuclein: implications for the pathogenesis of Parkinson disease. J. Biol. Chem. 284, 13128-13142
15. Eliezer, D., Kutluay, E., Bussell, R., Jr., and Browne, G. (2001) Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061-1073
16. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., Kittel, A., and Saitoh, T. (1995) The precursor protein of non-A β component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475
17. Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G., and Goedert, M. (1998) Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26292-26294
18. Lashuel, H. A., Overk, C. R., Oueslati, A., and Masliah, E. (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48
19. Ahn, K. J., Paik, S. R., Chung, K. C., and Kim, J. (2006) Amino acid sequence motifs and mechanistic features of the membrane translocation of α-synuclein. J. Neurochem. 97, 265-279
20. Ulmer, T. S., Bax, A., Cole, N. B., and Nussbaum, R. L. (2005) Structure and dynamics of micelle-bound human α-synuclein. J. Biol. Chem. 280, 9595-9603
21. Bodner, C. R., Maltsev, A. S., Dobson, C. M., and Bax, A. (2010) Differential phospholipid binding of α-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy. Biochemistry 49, 862-871
22. Kim, Y. S., Laurine, E., Woods, W., and Lee, S. J. (2006)Anovel mechanism of interaction between α-synuclein and biological membranes. J. Mol. Biol. 360, 386-397
23. Bussell, R., Jr., and Eliezer, D. (2004) Effects of Parkinson's disease-linked mutations on the structure of lipid-associated α-synuclein. Biochemistry 43, 4810-4818
24. Jo, E., Fuller, N., Rand, R. P., St George-Hyslop, P., and Fraser, P. E. (2002) Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein. J. Mol. Biol. 315, 799-807
25. Fares,M. B. Ait-Bouziad,N. Dikiy,I. Mbefo,M. K. Jovičić,A. Kiely,A. Holton,J. L. Lee,S. J. Gitler,A. D. Eliezer,D. Lashuel,H. A.2014The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cellsHum. Mol. Genet.234491-4509
26. Choi,W. Zibaee,S. Jakes,R. Serpell,L. C. Davletov,B. Crowther,R. A. Goedert,M.2004Mutation E46K increases phospholipid binding and assembly into filaments of human α-synuclein.FEBS Lett.576363-368
27. Perlmutter, J. D., Braun, A. R., and Sachs, J. N. (2009) Curvature dynamics of α-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms. J. Biol. Chem. 284, 7177-7189
28. El-Agnaf, O. M., Jakes, R., Curran, M. D., and Wallace, A. (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440, 67-70
29. Conway, K. A., Harper, J. D., and Lansbury, P. T., Jr. (2000) Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563
30. Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., Kaufman, S. A., Martin, F., Sitney, K., Denis, P., Louis, J. C., Wypych, J., Biere, A. L., and Citron, M. (1999) Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274, 9843-9846
31. Giasson, B. I., Uryu, K., Trojanowski, J. Q., and Lee, V. M. (1999) Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622
32. Greenbaum, E. A., Graves, C. L., Mishizen-Eberz, A. J., Lupoli, M. A., Lynch, D. R., Englander, S. W., Axelsen, P. H., and Giasson, B. I. (2005) The E46K mutation in α-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800-7807
33. Yonetani, M., Nonaka, T., Masuda, M., Inukai, Y., Oikawa, T., Hisanaga, S., and Hasegawa, M. (2009) Conversion of wild-type α-synuclein into mu-tant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem. 284, 7940-7950
34. Ghosh, D., Mondal, M., Mohite, G. M., Singh, P. K., Ranjan, P., Anoop, A., Ghosh, S., Jha, N. N., Kumar, A., and Maji, S. K. (2013) The Parkinson's disease-associated H50Q mutation accelerates α-synuclein aggregation in vitro. Biochemistry 52, 6925-6927
35. Li, J., Uversky, V. N., and Fink, A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 40, 11604-11613
36. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to earlyonset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 97, 571-576
37. Ghosh, D., Sahay, S., Ranjan, P., Salot, S., Mohite, G. M., Singh, P. K., Dwivedi, S., Carvalho, E., Banerjee, R., Kumar, A., and Maji, S. K. (2014) The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding. Biochemistry 53, 6419-6421
38. Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., Diep, L., Keim, P. S., Shen, X., Chataway, T., Schlossmacher, M. G., et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752
39. Emmer, K. L., Waxman, E. A., Covy, J. P., and Giasson, B. I. (2011) E46K human α-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J. Biol. Chem. 286, 35104-35118
40. Smith, W. W., Margolis, R. L., Li, X., Troncoso, J. C., Lee, M. K., Dawson, V. L., Dawson, T. M., Iwatsubo, T., and Ross, C. A. (2005) α-Synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25, 5544-5552
41. Ishii, A., Nonaka, T., Taniguchi, S., Saito, T., Arai, T., Mann, D., Iwatsubo, T., Hisanaga, S., Goedert, M., and Hasegawa, M. (2007) Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human α-synuclein: implication for α-synucleinopathies. FEBS Lett. 581, 4711-4717
42. Paleologou, K. E., Schmid, A. W., Rospigliosi, C. C., Kim, H. Y., Lamberto, G. R., Fredenburg, R. A., Lansbury, P. T., Jr., Fernandez, C. O., Eliezer, D., Zweckstetter, M., and Lashuel, H. A. (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of α-synuclein. J. Biol. Chem. 283, 16895-16905
43. Mbefo, M. K., Paleologou, K. E., Boucharaba, A., Oueslati, A., Schell, H., Fournier, M., Olschewski, D., Yin, G., Zweckstetter, M., Masliah, E., Kahle, P. J., Hirling, H., and Lashuel, H. A. (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285, 2807-2822
44. Hoyer, W., Antony, T., Cherny, D., Heim, G., Jovin, T. M., and Subramaniam, V. (2002) Dependence of α-synuclein aggregate morphology on solution conditions. J. Mol. Biol. 322, 383-393
45. Outeiro, T. F., and Lindquist, S. (2003) Yeast cells provide insight into α-synuclein biology and pathobiology. Science 302, 1772-1775
46. Mumberg, D., Müller, R., and Funk, M. (1995) Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene 156, 119-122
47. Premont, R. T. (1994) Identification of adenylyl cyclases by amplification using degenerate primers. Methods Enzymol. 238, 116-127
48. Dotan, I., Ziv, E., Dafni, N., Beckman, J. S., McCann, R. O., Glover, C. V., and Canaani, D. (2001) Functional conservation between the human, nematode, and yeast CK2 cell cycle genes. Biochem. Biophys. Res. Commun. 288, 603-609
49. Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T., and Masliah, E. (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in α-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 29, 13578-13588
50. Paleologou, K. E., Oueslati, A., Shakked, G., Rospigliosi, C. C., Kim, H. Y., Lamberto, G. R., Fernandez, C. O., Schmid, A., Chegini, F., Gai, W. P., Chiappe, D., Moniatte, M., Schneider, B. L., Aebischer, P., Eliezer, D., et al. (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits α-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 30, 3184-3198
51. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277-293
52. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J., and Haass, C. (2000) Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J. Biol. Chem. 275, 390-397
53. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., and Iwatsubo, T. (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160-164
54. Waxman, E. A., and Giasson, B. I. (2008) Specificity and regulation of casein kinase-mediated phosphorylation of α-synuclein. J. Neuropathol. Exp. Neurol. 67, 402-416
55. Inglis, K. J., Chereau, D., Brigham, E. F., Chiou, S. S., Schöbel, S., Frigon, N. L., Yu, M., Caccavello, R. J., Nelson, S., Motter, R., Wright, S., Chian, D., Santiago, P., Soriano, F., Ramos, C., et al. (2009) Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system. J. Biol. Chem. 284, 2598-2602
56. Salvi, M., Trashi, E., Marin, O., Negro, A., Sarno, S., and Pinna, L. A. (2012) Superiority of PLK-2 as α-synuclein phosphorylating agent relies on unique specificity determinants. Biochem. Biophys. Res. Commun. 418, 156-160
57. Landrieu, I., Lacosse, L., Leroy, A., Wieruszeski, J. M., Trivelli, X., Sillen, A., Sibille, N., Schwalbe, H., Saxena, K., Langer, T., and Lippens, G. (2006) NMR analysis of a Tau phosphorylation pattern. J. Am. Chem. Soc. 128, 3575-3583
58. Pronin, A. N., Morris, A. J., Surguchov, A., and Benovic, J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26515-26522
59. Sakamoto, M., Arawaka, S., Hara, S., Sato, H., Cui, C., Machiya, Y., Koyama, S., Wada, M., Kawanami, T., Kurita, K., and Kato, T. (2009) Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of α-synuclein in HEK293 cells. Biochem. Biophys. Res. Commun. 384, 378-382
60. Chau, K. Y., Ching, H. L., Schapira, A. H., and Cooper, J. M. (2009) Relationship between α-synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J. Neurochem. 110, 1005-1013
61. Machiya, Y., Hara, S., Arawaka, S., Fukushima, S., Sato, H., Sakamoto, M., Koyama, S., and Kato, T. (2010) Phosphorylated α-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J. Biol. Chem. 285, 40732-40744
62. Neznanov, N., Dragunsky, E. M., Chumakov, K. M., Neznanova, L., Wek, R. C., Gudkov, A. V., and Banerjee, A. K. (2008) Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. PLoS One 3, e1887
63. Boone, A. N., and Vijayan, M. M. (2002) Glucocorticoid-mediated attenuation of the hsp70 response in trout hepatocytes involves the proteasome. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R680-R687
64. Gilon, T., Chomsky, O., and Kulka, R. G. (1998) Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae. EMBO J. 17, 2759-2766
65. Nonaka, T., and Hasegawa, M. (2009) A cellular model to monitor proteasome dysfunction by α-synuclein. Biochemistry 48, 8014-8022
66. Xu, S., Zhou, M., Yu, S., Cai, Y., Zhang, A., Uéda, K., and Chan, P. (2006) Oxidative stress induces nuclear translocation of C-terminus of α-synuclein in dopaminergic cells. Biochem. Biophys. Res. Commun. 342, 330-335
67. Zhou, M., Xu, S., Mi, J., Uéda, K., and Chan, P. (2013) Nuclear translocation of α-synuclein increases susceptibility of MES23.5 cells to oxidative stress. Brain Res. 1500, 19-27
68. Colla, E., Jensen, P. H., Pletnikova, O., Troncoso, J. C., Glabe, C., and Lee,M. K. (2012) Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J. Neurosci. 32, 3301-3305
69. Wakamatsu, M., Ishii, A., Ukai, Y., Sakagami, J., Iwata, S., Ono, M., Matsumoto, K., Nakamura, A., Tada, N., Kobayashi, K., Iwatsubo, T., and Yoshimoto, M. (2007) Accumulation of phosphorylated α-synuclein in dopaminergic neurons of transgenic mice that express human α-synuclein. J. Neurosci. Res. 85, 1819-1825
70. Colla, E., Coune, P., Liu, Y., Pletnikova, O., Troncoso, J. C., Iwatsubo, T., Schneider, B. L., and Lee, M. K. (2012) Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J. Neurosci. 32, 3306-3320
71. Kiely, A. P., Asi, Y. T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., Quinn, N., Lees, A. J., Hardy, J., Revesz, T., Houlden, H., and Holton, J. L. (2013) α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol. 125, 753-769
72. Jiang, M., Porat-Shliom, Y., Pei, Z., Cheng, Y., Xiang, L., Sommers, K., Li, Q., Gillardon, F., Hengerer, B., Berlinicke, C., Smith, W. W., Zack, D. J., Poirier, M. A., Ross, C. A., and Duan, W. (2010) Baicalein reduces E46K α-synuclein aggregation in vitro and protects cells against E46K α-synuclein toxicity in cell models of familiar Parkinsonism. J. Neurochem. 114, 419-429
73. Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D., and Greene, L. A. (2001) Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549-9560
74. Tanaka, Y., Engelender, S., Igarashi, S., Rao, R. K., Wanner, T., Tanzi, R. E., Sawa, A., V, L. D., Dawson, T. M., and Ross, C. A. (2001) Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919-926
75. Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., Stefanis, L., and Vekrellis, K. (2010) Cellproduced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838-6851
76. Martìn-Clemente, B., Alvarez-Castelao, B., Mayo, I., Sierra, A. B., Dìaz, V., Milán, M., Fariñas, I., Gómez-Isla, T., Ferrer, I., and Castaño, J. G. (2004) α-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines. J. Biol. Chem. 279, 52984-52990
77. McNaught, K. S., and Jenner, P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191-194
78. Huang, Z., Xu, Z., Wu, Y., and Zhou, Y. (2011) Determining nuclear localization of α-synuclein in mouse brains. Neuroscience 199, 318-332
79. Schell, H., Hasegawa, T., Neumann, M., and Kahle, P. J. (2009) Nuclear and neuritic distribution of serine-129 phosphorylated α-synuclein in transgenic mice. Neuroscience 160, 796-804